Browse / Retatrutide
Triple GIP/GLP-1/glucagon agonist · metabolic research
Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. Phase 2 obesity-trial data (NEJM) reported large mean weight-change figures in a clinical-development setting. Shop vials are research materials, not a licensed drug product. All catalog material is for laboratory research use only.
Triple incretin/glucagon pharmacology, large phase-2 weight-change signals (mid-20% range cited in that trial setting), glycemic secondary measures, additional energy-expenditure interest from glucagon-receptor activity versus dual agonists.
Simultaneous incretin and glucagon-receptor engagement is studied for energy expenditure, appetite signaling, and glycemic markers. Glucagon-receptor activity is a differentiator versus dual GIP/GLP-1 agonists.
Triple incretin agonist (GLP-1/GIP/glucagon analog); full primary structure on certificate.
Clinical PK from development trials, not a use schedule.
Age verification
The products on this website are only for research professionals of 21+ years of age, purchasing for research purposes only. Any human or animal consumption is strictly prohibited.
Research Use Only — not for human or animal consumption.
You must be at least 21 years old to enter this website. Please leave and return when you meet the age requirement.